Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Abstract

The HIV incidence with twice-yearly lenacapavir was significantly lower than the background incidence and the incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 2 ClinicalTrials.gov number, NCT04925752.).